[1] Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabete-induced arterial wall protein cross-linking [J]. Science, 1986, 232(4758)∶1629-1632 [2] Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal methylglyoxal and 3-deoxy glucosone in the glycation of proteins by glucose [J]. Biochem, 1999, 344∶109-116 [3] Enomoto M, Adachi H, Yamagishi S, et al. Positive association of serum levels of advanced glycation end products with thrombogenic makers in humans [J]. Metabolism, 2006, 55(5)∶912-917 [4] Wada S,Kamiya S,Fukawa T. Bone quality change in diabetes [J]. Clin Calcium,2008,18(5)∶600 [5] Guoliang H, Ying Z. Valuation and countermeasure of Diabetic Osteoporosis [J]. Journal of Practical Diabetology,2006,2(4)∶4-6[6] Schwartz AV. Diabetes mellitus: does it affect bone [J]. Calcified tissue international,2003,73(6)∶515-519 [7] Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs) ,but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppre ssion of osterix expression, and inhibit cell growth and increasing cell apoptosis [J]. Calcif Tissue Int,2012,91(4)∶286-96 [8] Kuo MY, Hsu HY, Kok SH, et al. Prognostic role of p27(Kip1)expression in oral squamous cell carcinoma in Taiwan [J]. Oral Oncol,2002,38(2)∶172-217 [9] Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy [J]. Nat Rev Cancer,2008,8(4)∶253-267 |